Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
19 drugs for “Breast Cancer”
Approved 10
- AbemaciclibELI LILLY & CoBreast Cancer
- AlpelisibNOVARTIS AGBreast Cancer; Advanced HER2+Breast Cancer
- CamizestrantASTRAZENECA PLCBreast Cancer, Early Breast Cancer; Advanced Breast Cancer; ER-Positive HER2-Negative Breast Cancer
- CapivasertibASTRAZENECA PLCLocally Advanced (Inoperable) or Metastatic Breast Cancer; Breast Cancer; Locally Advanced or Metastatic Breast Cancer
- DurvalumabASTRAZENECA PLCBreast Cancer
- GedatolisibCelcuity Inc.Breast Cancer
- NeratinibPUMA BIOTECHNOLOGY, INC.Breast Cancer; HER2+ Metastatic Breast Cancer (MBC)
- PalbociclibPFIZER INCBreast Cancer; Advanced Breast Cancer Female; Metastatic Breast Cancer
- RibociclibNOVARTIS AGBreast Cancer; Advanced Metastatic Breast Cancer; Early Breast Cancer
- TucatinibSeagen Inc.HER2 Positive Breast Cancer
Phase 3 9
- AnsastrozoleNOVARTIS AGEarly Breast Cancer
- ARV-471PFIZER INCAdvanced Breast Cancer
- AZD9833ASTRAZENECA PLCER-Positive HER2-Negative Breast Cancer
- BGB-43395BeOne Medicines Ltd.HR+/HER2- Breast Cancer
- GLSI-100Greenwich LifeSciences, Inc.Breast Cancer
- PalazestrantOlema Pharmaceuticals, Inc.Breast Cancer; ER Positive Breast Cancer; Metastatic Breast Cancer
- SaruparibASTRAZENECA PLCAdvanced Breast Cancer
- VeliparibAbbVie Inc.Metastatic Breast Cancer
- ZovegalisibRelay Therapeutics, Inc.Advanced Breast Cancer; Breast Cancer; HER2- Negative Breast Cancer
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.